I think we first have to clarify the existing situation, which is that safety concerns are generally evaluated at the federal level by TPD or by BGTD at Health Canada; then the funding decisions are made on the provincial basis, and that's likely what the JODR is going to look at in terms of oncology products.
In my presentation I was referring to the harmonization or unification of this type of process. One of the things that I think would be very important to take away is that when it comes at least to the oncology products, an earlier review could be started at the time that Health Canada is evaluating the safety of the product, so as not to lose time and have an additional delay down the track.
I think in at least one case or so, CDR has attempted to do that in order not to add to the eventual delays. This becomes of paramount importance when we're talking about cancer medications, because this is life or death, as opposed to the situation with other medications, which may not necessarily be life or death. I think you actually alluded, maybe unwittingly, to the whole connection between the shortening of the delays between the decisions being made for reimbursement and the safety concerns. I think that opportunity should be looked into.